{"id":"NCT04569357","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children","officialTitle":"Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-20","primaryCompletion":"2022-02-18","completion":"2022-02-18","firstPosted":"2020-09-29","resultsPosted":"2024-08-01","lastUpdate":"2024-08-01"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Prospekta","otherNames":["MMH-MAP"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Prospekta","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Purpose of the study:\n\n• evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.","primaryOutcome":{"measure":"Percentage of Patients With Total ADHD-RS-V Reduction ≥25%","timeFrame":"After 8 weeks of treatment","effectByArm":[{"arm":"Prospekta","deltaMin":95,"sd":null},{"arm":"Placebo","deltaMin":81,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0199"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":174},"commonTop":["Viral infection of the respiratory tract","Headache","Vomiting","Dyspepsia","Upper respiratory tract infection"]}}